ArticleFrontiers in public health2026
Associations between prenatal phthalate exposure and maternal immune cell profiles across trimesters.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Phthalates (PAEs) are endocrine-disrupting chemicals, yet the association between prenatal PAE exposure and maternal blood immune cells remains unclear. Here, we enrolled 2,581 pregnant women, including 287 in the first trimester (gestational weeks 1-12), 807 in the second trimester (gestational weeks 13-27), and 1,487 in the third trimester (gestational weeks 28 to delivery). This study aimed to elucidate the association between urinary phthalates (PAEs) metabolites during pregnancy and characteristics of the maternal immune cell profile. Methods: First, we analyzed differences in maternal PAE metabolites and immune cell counts (leukocytes, lymphocytes, neutrophils, eosinophils, basophils, monocytes, and platelets) in the three gestational stages using non-parametric alternatives (Kruskal-Wallis test). Subsequently, linear regression models quantified correlations between PAE metabolites and immune cell counts, while restricted cubic spline (RCS) analysis explored dose-response relationships between the two. Finally, Bayesian kernel machine regression (BKMR) was used to assess the non-linear associated between PAE metabolites and immune cells. Results: Findings revealed pregnancy-stage differences in both maternal PAE metabolites and maternal immune cell counts within each trimester. Linear regression identified significant associations between specific PAE metabolites and immune cell subsets, while RCS models further confirmed dose-response relationships for multiple metabolites. BKMR analysis highlighted a nonlinear association between combined exposure to PAE metabolites and basophils, monocytes, and lymphocytes. Discussion: In summary, this study has preliminarily established an association between prenatal maternal exposure to PAE metabolites and immune cells in maternal blood, highlighting the potential immunomodulatory effects of PAE exposure during pregnancy. However, as this study is primarily based on epidemiological research, all findings should be interpreted with caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.